Bionovo Inc. (NASDAQ:BNVI) has the 1st highest upside potential in this segment of the market. Its upside is 782.4%. Its consensus target price is $7.50 based on the average of all estimates.Tengion, Inc. (NASDAQ:TNGN) has the 2nd highest upside potential in this segment of the market. Its upside is 669.2%. Its consensus target price is $9.00 based on the average of all estimates.NeurogesX, Inc (NASDAQ:NGSX) has the 3rd highest upside potential in this segment of the market. Its upside is 452.3%. Its consensus target price is $9.50 based on the average of all estimates.Palatin Technologies, Inc. (AMEX:PTN) has the 4th highest upside potential in this segment of the market. Its upside is 371.7%. Its consensus target price is $5.00 based on the average of all estimates. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has the 5th highest upside potential in this segment of the market. Its upside is 364.5%. Its consensus target price is $8.50 based on the average of all estimates.
Cytokinetics, Inc. (NASDAQ:CYTK) has the 6th highest upside potential in this segment of the market. Its upside is 362.2%. Its consensus target price is $5.50 based on the average of all estimates. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 7th highest upside potential in this segment of the market. Its upside is 342.3%. Its consensus target price is $9.33 based on the average of all estimates.NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has the 8th highest upside potential in this segment of the market. Its upside is 327.4%. Its consensus target price is $4.32 based on the average of all estimates. Peregrine Pharmaceuticals (NASDAQ:PPHM) has the 9th highest upside potential in this segment of the market. Its upside is 323.0%. Its consensus target price is $8.33 based on the average of all estimates. MediciNova, Inc. (NASDAQ:MNOV) has the 10th highest upside potential in this segment of the market. Its upside is 316.7%. Its consensus target price is $10.50 based on the average of all estimates.
No comments:
Post a Comment